Argan Inc SEC Filings

Argan, Inc. (AGX) – Form 4 Insider Transaction Summary

Director Peter W. Getsinger reported three transactions involving the company’s common stock:

• Sale: On 26 Jun 2025, he sold 3,456 shares in the open market at $212.01 per share, generating roughly $732.7 thousand in proceeds.
• Gift to Donor-Advised Fund: On 30 Jun 2025, he transferred 1,000 shares at no consideration to a donor-advised fund managed by Martha’s Vineyard Investment Advisors.
• Family Gift: On the same date, he gifted 999 shares (333 shares each) to his three children.

Following these transactions, Getsinger’s direct beneficial ownership declined from 18,351 to 12,896 shares, a 29.7 % reduction. No derivative securities were reported.

The filing does not indicate that the sale was executed under a Rule 10b5-1 trading plan. Investors often view sizeable insider sales—particularly absent a preset plan—as a potential negative sentiment signal, although philanthropic gifts may be neutral with respect to corporate outlook.

Argan, Inc. (AGX) Form 4 filing: Director William F. Leimkuhler disclosed two open-market sales of the company’s common stock.

• On 27-Jun-2025, he sold 4,051 shares at an average price of $221.25.
• On 30-Jun-2025, he sold 7,604 shares at an average price of $222.03.

The combined sale of 11,655 shares generated proceeds of roughly $2.6 million (based on the reported average prices). After the transactions, Leimkuhler’s direct ownership declined from 58,240 to 50,636 shares, a reduction of about 13%. No derivative securities activity was reported.

The filing signals insider selling by a non-executive director; investors often view such activity as a potential indicator of reduced near-term confidence, though it may also reflect personal portfolio decisions rather than a view on fundamentals.

Form 4 Filing Details: Peter W. Getsinger, Director of Argan (AGX), exercised stock options and acquired shares on June 23, 2025. Key transaction details:

• Exercised 10,000 stock options at $71.75 per share using net settlement method
• Options were originally awarded on January 5, 2017, with expiration date of January 5, 2027
• Acquired 6,465 common shares through this transaction
• Post-transaction holdings: 18,351 direct common shares and 34,500 remaining stock options

This insider transaction represents a standard option exercise by a board member, with the net settlement method resulting in fewer shares being issued than the original option amount due to covering the exercise cost.

Form 4 overview: On 06/17/2025, Argan, Inc. (AGX) director Peter W. Getsinger reported the award of 530 Time-Based Restricted Stock Units (TRSUs) with an exercise price of $0. These derivative securities can convert into an equal number of common shares once vested.

Vesting schedule: The TRSUs will vest completely on 04/17/2026, provided the director remains in service. No non-derivative share transactions, sales, or additional purchases were disclosed.

Post-transaction holdings: Following the grant, Getsinger now beneficially owns 3,947 derivative securities tied to AGX common stock, all held directly. The filing does not indicate any change to his direct common-share ownership.

Investor relevance: The grant appears to be routine board compensation. Given the small size—530 units—the award is immaterial relative to Argan’s public float and is unlikely to influence share supply, earnings per share, or short-term insider-sentiment indicators.

Key takeaway: On 17 June 2025, Argan, Inc. (AGX) filed a Form 4 showing that director Cynthia Flanders received 530 time-based restricted stock units (RSUs) under the company’s equity incentive plan.

The RSUs were reported under Transaction Code “A” (grant/acquisition) at a price of $0, meaning no cash changed hands. According to the footnote, the entire block will vest on 17 June 2026, at which point each RSU converts into one share of common stock.

After this award, Ms. Flanders now beneficially owns 3,947 RSUs in total, all held directly. The filing contains no sales, exercises, or disposals, and there is no indication that the award was made under a Rule 10b5-1 trading plan.

Because the grant involves a small number of shares relative to Argan’s total shares outstanding and is routine director compensation, it carries minimal immediate financial or dilution impact. Investors may, however, view the award as part of standard governance practice that aligns director incentives with shareholder interests.

Argan director William F. Leimkuhler reported receiving 530 Time-Based Restricted Stock Units (TRSUs) on June 17, 2025. The TRSUs, which have a conversion price of $0, represent the right to receive an equivalent number of Argan common stock shares.

Key details of the transaction:

• The TRSUs will fully vest on April 17, 2026
• Following the transaction, Leimkuhler beneficially owns 3,947 derivative securities directly
• The grant appears to be part of the company's director compensation program

This Form 4 filing, submitted on June 28, 2025, complies with SEC regulations requiring insiders to report changes in their beneficial ownership of company securities within two business days of the transaction.

Karen Sweeney, Director at Argan (AGX), reported multiple transactions involving Time-Based Restricted Stock Units (TRSUs):

• On June 20, 2025, 1,300 TRSUs vested and were converted to common stock (adjusted for dividends, resulting in 1,315 shares) following a one-year vesting schedule from the June 2024 award
• On June 17, 2025, received a new grant of 530 TRSUs, scheduled to vest fully on April 17, 2026

Following these transactions, Sweeney directly owns 1,705 shares of common stock and 530 unvested TRSUs. All transactions were executed at $0 exercise price, consistent with typical TRSU arrangements. These equity awards are part of the company's director compensation program.

James W. Quinn, Director of Argan (NYSE: AGX), received a new grant of 530 Time-Based Restricted Stock Units (TRSUs) on June 17, 2025. This equity compensation award represents part of the director's compensation package.

Key details of the transaction:

• The TRSUs have a $0 exercise price
• Full vesting is scheduled for April 17, 2026
• Each TRSU converts to one share of common stock
• Following this grant, Quinn beneficially owns 3,947 TRSUs directly

The filing was reported through Form 4 on June 20, 2025, within the required reporting window for insider transactions. Quinn serves as a non-employee director and is not a 10% owner of the company. The grant appears to be part of the company's standard director compensation program.